SCHEMBL4152606

SCHEMBL4152606

NC(=O)c1ccc(Oc2cc(F)ccc2F)o1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 6/20 0.40
ALDH1A1 P00352 5/20 0.39
MAPT P10636 3/20 0.39
PARP10 Q53GL7 1/20 0.37
PARP1 P09874 3/20 0.36
KDM4E B2RXH2 2/20 0.36
LMNA P02545 1/20 0.36
PRNP P04156 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
KMT2A Q03164 1/20 0.35
GAA P10253 1/20 0.34
CYP4F2 P78329 1/20 0.34
CYP4A11 Q02928 1/20 0.34
NPSR1 Q6W5P4 1/20 0.33
ALOX5 P09917 1/20 0.33
POLB P06746 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4168235 0.88 BRD4 (0.41) SLC9A1PARP10LMNA
SCHEMBL4155325 0.77 ALDH1A1 (0.45) SLC9A1ALDH1A1MAPTPARP10PARP1
SCHEMBL1680394 0.73 CYP2E1 (0.34)
SCHEMBL1680748 0.73 ALDH1A1 (0.46) ALDH1A1KDM4ELMNAHPGDCES2
SCHEMBL6157961 0.71 ALDH1A1 (0.71) SLC9A1ALDH1A1MAPTKDM4ELMNA
SCHEMBL9487857 0.69 CA3 (0.46) ALDH1A1CES2CES1KMT2A
SCHEMBL28015642 0.69 CES2 (0.45) SLC9A1ALDH1A1MAPTPARP10PARP1
SCHEMBL4155326 0.68 PARP10 (0.50) SLC9A1ALDH1A1MAPTPARP10NPSR1
SCHEMBL15218337 0.66 ALDH1A1 (0.69) SLC9A1ALDH1A1MAPTKDM4ELMNA
SCHEMBL3643463 0.65 PARP10 (0.67) ALDH1A1PARP10PARP1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-09-10 US disclosed
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2007-05-10 US disclosed
EP-1782811-A1 NOVEL ANTIMALARIA AGENT CONTAINING HETEROCYCLIC COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-05-09 EP disclosed
EP-1669348-A1 NOVEL ANTIFUNGAL AGENT COMPRISING HETEROCYCLIC COMPOUND Eisai Co., Ltd. (JP) 2006-06-14 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227799-A1 Novel Antimalarial Agent Containing Heterocyclic Compound XPO1, THPO, G6PD SLC9A1 923/4885ALDH1A1 1926/4885MAPT 4227/4885
US-20070105943-A1 Novel antifungal agent containing heterocyclic compound ERG28, DPM1, CYP51A1 SLC9A1 3204/4885ALDH1A1 1459/4885MAPT 4111/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.